Does the legalisation of cannabis for medicinal use impact private health insurer prescription drug expenditures?

<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<rdf:Description>
<dc:creator>Cook, Amanda C.</dc:creator>
<dc:creator>Tice Sirmans, E.</dc:creator>
<dc:creator>Wells, Brenda </dc:creator>
<dc:date>2024-01-02</dc:date>
<dc:description xml:lang="es">Sumario: We evaluate whether health insurer aggregate prescription drug expenditures change after the legalisation of medicinal cannabis using U.S. health insurer financial filings reported to state insurance regulators and compiled by the National Association of Insurance Commissioners for private health insurers from 2010 to 2018. We analyse this question for health insurers in the individual market, which includes plans sold on the Affordable Care Act exchanges, the small group market, which consists of fully insured plans sold to employers with fewer than 50 employees, and the large group market, which consists of fully insured plans sold to employers with more than 50 employees. For all three markets, the treatment effects are not significant. Thus, we find no impact of medical cannabis legalisation on health insurer prescription drug expenditures, despite the potential disruption to the health insurance market. Had legalisation increased prescription drug expenditures, the increases in cost would have been borne by enrollees, which is troubling since healthcare costs are rising faster than inflation</dc:description>
<dc:identifier>https://documentacion.fundacionmapfre.org/documentacion/publico/es/bib/184777.do</dc:identifier>
<dc:language>spa</dc:language>
<dc:rights xml:lang="es">InC - http://rightsstatements.org/vocab/InC/1.0/</dc:rights>
<dc:subject xml:lang="es">Seguro de asistencia sanitaria</dc:subject>
<dc:subject xml:lang="es">Seguro de salud</dc:subject>
<dc:subject xml:lang="es">Legislación</dc:subject>
<dc:subject xml:lang="es">Medicamentos</dc:subject>
<dc:subject xml:lang="es">Drogas</dc:subject>
<dc:subject xml:lang="es">Sistema de distribución de medicamentos</dc:subject>
<dc:subject xml:lang="es">Costes económicos</dc:subject>
<dc:subject xml:lang="es">Estados Unidos</dc:subject>
<dc:type xml:lang="es">Artículos y capítulos</dc:type>
<dc:title xml:lang="es">Does the legalisation of cannabis for medicinal use impact private health insurer prescription drug expenditures?</dc:title>
<dc:relation xml:lang="es">En: Geneva papers on risk and insurance : issues and practice. - Geneva : The Geneva Association, 1976- = ISSN 1018-5895. - 02/01/2024 Volumen 49 Número 1 - enero 2024 , 15 p.</dc:relation>
<dc:coverage xml:lang="es">Estados Unidos</dc:coverage>
</rdf:Description>
</rdf:RDF>